ReviewCureus2018
Interleukins Associated with Breast Cancer.
Review in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 63 citations in OpenAlex.
- An Internet Mantram Repetition Program to Promote Well-being in Breast Cancer Survivors: A Feasibility Randomized Controlled Trial.Integrative cancer therapiesTrial
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- The Inflammatory Footprint of Anti-Breast Cancer Treatments and Psychosocial Factors in Women Undergoing Chemotherapy.Biomedicines · 2025Article
- Differential expression of cytokines and vitamin D in benign and malignant thyroid diseases.Scientific reports · 2025Article
- The impact of serum interleukin-17a as a predictive biomarker for neoadjuvant therapy response in breast cancer: a retrospective study.Gland surgery · 2025Article
- In silico identification and in vitro evaluation of MRPS30-DT lncRNA and MRPS30 gene expression in breast cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- Oxidative Stress in Breast Cancer: A Biochemical Map of Reactive Oxygen Species Production.Current issues in molecular biology · 2024Review
- Type II Interleukin-4 Receptor Activation in Basal Breast Cancer Cells Promotes Tumor Progression via Metabolic and Epigenetic Modulation.International journal of molecular sciences · 2024Article
- Understanding crosstalk of organ tropism, tumor microenvironment and noncoding RNAs in breast cancer metastasis.Molecular biology reports · 2023Review
- Vaccines in Breast Cancer: Challenges and Breakthroughs.Diagnostics (Basel, Switzerland) · 2023Review
- Interleukine-2 serum level in breast cancer patients.Caspian journal of internal medicine · 2023Article
- Hybrid computational modeling highlights reverse warburg effect in breast cancer-associated fibroblasts.Computational and structural biotechnology journal · 2023Article
- Development of a nomogram based on serum cytokine-related riskscore in breast cancer.Frontiers in oncology · 2023Article
- The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target.Frontiers in immunology · 2023Review
- Article
- Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers.Journal of translational medicine · 2022Article
- Relationship Between IL-2, IL-17 Concentrations, and Serum Creatinine Levels in Men with Chronic Kidney Diseases.Reports of biochemistry & molecular biology · 2022Article
- IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer.Frontiers in oncology · 2022Article
- Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.Journal of cellular and molecular medicine · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A tumor consists of a group of cells with abnormal growth, capable of acquiring unique characteristics that provide them with the ability to display mercurial migration patterns, adapting to microenvironments and their chemical and physical factors. Interleukins are small proteins secreted mainly by CD3+ and CD4+ T lymphocytes that mediate the "essential for cancer progression" interactions between cells. Interleukins are implicated in both the development and differentiation of different cells (NK, B, and T leukocytes) and, in general, play a major role in many diseases, including breast cancer, due to their unique participation in systemic inflammation and immune system modulation. During the past decade, interleukins proved to be decisive for future immunotherapy, predisposing a more reliable treatment with fewer side effects on normal proliferating cells. The aim of this review is to provide an overview of the role of interleukins implicated in breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.